Last update 01 Nov 2024
Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao)
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms 重组抗PEAR1单克隆抗体 + [1] |
Target |
Mechanism PEAR1 inhibitors(platelet endothelial aggregation receptor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao)A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
单中心、随机、双盲、单次给药、剂量递增、安慰剂对照设计，评价SV001雾化吸入溶液在中国健康成年受试者中的安全性、耐受性、药代动力学特征和免疫原性的I期临床试验
[Translation] A single-center, randomized, double-blind, single-dose, dose-escalation, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of SV001 nebulized inhalation solution in healthy Chinese adult subjects
A randomized, double-blind, placebo-controlled clinical study for 52 weeks to evaluate the effect of recombinant anti human GLP-1 receptor humanized monoclonal antibody injection on blood glucose fluctuation and bone metabolism in patients with type 2 diabetes
100 Clinical Results associated with Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao)
Login to view more data
100 Translational Medicine associated with Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao)
Login to view more data
100 Patents (Medical) associated with Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao)
Login to view more data
100 Deals associated with Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | Phase 1 | CN | 08 Jan 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free